Melanoma vaccine - Pierre Fabre

Drug Profile

Melanoma vaccine - Pierre Fabre

Alternative Names: F-50040; P40/ELA; Project F 50 040

Latest Information Update: 12 Mar 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ludwig Institute for Cancer Research
  • Developer Pierre Fabre
  • Class Cancer vaccines; Peptides; Proteins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Malignant melanoma

Most Recent Events

  • 12 Mar 2008 Disconintued - Phase-I for Malignant melanoma in France (Parenteral)
  • 28 Oct 2005 Phase-I clinical trials in Malignant melanoma in France (unspecified route)
  • 11 Jul 2001 Preclinical development for Malignant melanoma in France (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top